(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Medigus Ltd., Rumble, and Snap.

The three biggest losers today are ObsEva SA, OncoSec Medical Incorporated, and MMTec.

Winners today

1. Medigus Ltd. (MDGSW) – 67.33%

NASDAQ ended the session with Medigus Ltd. rising 67.33% to $0.07 on Monday while NASDAQ dropped 0.11% to $11,675.74.

More news about Medigus Ltd..

2. Rumble (RUM) – 10.02%

Rumble Inc. operates video sharing platforms. The company operates rumble.com, a platform that enables video creators to host, livestream, manage, distribute, and create OTT feeds, as well as monetize their content. It also operates locals.com, a subscription-based video sharing platform. The company was founded in 2013 and is based in Longboat Key, Florida.

NASDAQ ended the session with Rumble jumping 10.02% to $9.33 on Monday while NASDAQ dropped 0.11% to $11,675.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.11%.

Volatility

Rumble’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.93%, a negative 1.49%, and a positive 4.05%.

Rumble’s highest amplitude of average volatility was 3.71% (last week), 4.23% (last month), and 4.05% (last quarter).

Moving Average

Rumble’s worth is above its 50-day moving average of $8.64 and under its 200-day moving average of $10.12.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Rumble’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 430.7%, now sitting on 22.37M for the twelve trailing months.

More news about Rumble.

3. Snap (SNAP) – 9.39%

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, story ads, collection ads, dynamic ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.

NYSE ended the session with Snap rising 9.39% to $11.65 on Monday while NYSE fell 0.15% to $15,697.23.

Earnings Per Share

As for profitability, Snap has a trailing twelve months EPS of $-0.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.88%.

Volume

Today’s last reported volume for Snap is 73560000 which is 133.84% above its average volume of 31456700.

Sales Growth

Snap’s sales growth is negative 5.3% for the current quarter and negative 0.7% for the next.

Volatility

Snap’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.92%, a negative 0.88%, and a positive 2.92%.

Snap’s highest amplitude of average volatility was 2.17% (last week), 2.87% (last month), and 2.92% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 4.6B for the twelve trailing months.

More news about Snap.

4. SmileDirectClub (SDC) – 7.98%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub rising 7.98% to $0.54 on Monday while NASDAQ slid 0.11% to $11,675.74.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.334.

Revenue Growth

Year-on-year quarterly revenue growth declined by 22.5%, now sitting on 510.5M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 16% and 26.3%, respectively.

More news about SmileDirectClub.

5. Kaixin Auto Holdings (KXIN) – 7.6%

Kaixin Auto Holdings operates as a used car dealership in the People's Republic of China. As of December 31, 2020, the company had 14 dealerships. It also provides financing channels to its customers through its partnership with financial institutions; and value-added services to its customers, including insurance, extended warranties, and after-sales services. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China. Kaixin Auto Holdings is a subsidiary of Renren Inc.

NASDAQ ended the session with Kaixin Auto Holdings jumping 7.6% to $0.52 on Monday, after three successive sessions in a row of gains. NASDAQ slid 0.11% to $11,675.74, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Kaixin Auto Holdings has a trailing twelve months EPS of $-0.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -447.04%.

Moving Average

Kaixin Auto Holdings’s value is way higher than its 50-day moving average of $0.42 and way under its 200-day moving average of $0.70.

More news about Kaixin Auto Holdings.

6. LIZHI (LIZI) – 7.47%

Lizhi Inc. operates an online user-generated content audio community, interactive audio entertainment platform, and online audio platform in China and the United States. It provides podcasts, live streaming, and audio entertainment products. The company also offers Lizhi app that allows users to record and share their voices on mobile devices; Tiya App, an audio-based social networking product; and LIZHI Podcast, a podcast app to provide curated podcast content. The company has collaboration agreements with Xpeng Motors, GAC AION New Energy Automobile, and GAC Motor, as well as with BYD DiLink and Huawei Mobile Services. Lizhi Inc. was incorporated in 2010 and is headquartered in Guangzhou, the People's Republic of China.

NASDAQ ended the session with LIZHI rising 7.47% to $0.88 on Monday while NASDAQ fell 0.11% to $11,675.74.

Earnings Per Share

As for profitability, LIZHI has a trailing twelve months EPS of $0.18.

PE Ratio

LIZHI has a trailing twelve months price to earnings ratio of 4.88. Meaning, the purchaser of the share is investing $4.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.27%.

Yearly Top and Bottom Value

LIZHI’s stock is valued at $0.88 at 16:32 EST, way below its 52-week high of $2.34 and way above its 52-week low of $0.38.

Moving Average

LIZHI’s value is below its 50-day moving average of $0.92 and below its 200-day moving average of $0.91.

Sales Growth

LIZHI’s sales growth is negative 0.4% for the ongoing quarter and negative 7.6% for the next.

More news about LIZHI.

7. MeiraGTx Holdings plc (MGTX) – 7.11%

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.

NASDAQ ended the session with MeiraGTx Holdings plc jumping 7.11% to $8.13 on Monday, following the last session’s upward trend. NASDAQ slid 0.11% to $11,675.74, after two consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, MeiraGTx Holdings plc has a trailing twelve months EPS of $-1.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.28%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 122.7% and positive 24.3% for the next.

Moving Average

MeiraGTx Holdings plc’s worth is way above its 50-day moving average of $7.22 and above its 200-day moving average of $7.76.

Yearly Top and Bottom Value

MeiraGTx Holdings plc’s stock is valued at $8.13 at 16:32 EST, way below its 52-week high of $15.16 and way higher than its 52-week low of $5.70.

Volume

Today’s last reported volume for MeiraGTx Holdings plc is 126281 which is 31.92% below its average volume of 185493.

More news about MeiraGTx Holdings plc.

8. Kura Sushi USA (KRUS) – 6.88%

Kura Sushi USA, Inc. operates technology-enabled Japanese restaurants in the United States. The company's restaurants offer Japanese cuisine through a revolving sushi service model. It operates 28 restaurants across six states. The company was formerly known as Kula Sushi USA, Inc. and changed its name to Kura Sushi USA, Inc. in October 2017. The company was founded in 2008 and is headquartered in Irvine, California. Kura Sushi USA, Inc. is a subsidiary of Kura Sushi, Inc.

NASDAQ ended the session with Kura Sushi USA jumping 6.88% to $68.02 on Monday, after four successive sessions in a row of gains. NASDAQ slid 0.11% to $11,675.74, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Kura Sushi USA has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.73%.

Volume

Today’s last reported volume for Kura Sushi USA is 179708 which is 14.75% above its average volume of 156603.

Yearly Top and Bottom Value

Kura Sushi USA’s stock is valued at $68.02 at 16:32 EST, way under its 52-week high of $96.60 and way higher than its 52-week low of $30.95.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Kura Sushi USA’s EBITDA is -1.74.

More news about Kura Sushi USA.

9. InVivo Therapeutics Holdings Corp. (NVIV) – 6.73%

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with InVivo Therapeutics Holdings Corp. jumping 6.73% to $2.06 on Monday, following the last session’s upward trend. NASDAQ slid 0.11% to $11,675.74, after two consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, InVivo Therapeutics Holdings Corp. has a trailing twelve months EPS of $-7.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -61.96%.

Yearly Top and Bottom Value

InVivo Therapeutics Holdings Corp.’s stock is valued at $2.06 at 16:32 EST, way under its 52-week high of $13.77 and way higher than its 52-week low of $1.61.

Earnings Before Interest, Taxes, Depreciation, and Amortization

InVivo Therapeutics Holdings Corp.’s EBITDA is 2.2.

More news about InVivo Therapeutics Holdings Corp..

10. StoneCo (STNE) – 6.4%

StoneCo Ltd. provides financial technology solutions to merchants and integrated partners to conduct electronic commerce across in-store, online, and mobile channels in Brazil. It distributes its solutions, principally through proprietary Stone Hubs, which offer hyper-local sales and services; and technology and solutions to digital merchants through sales and technical personnel and software vendors, as well as sells solutions to brick-and-mortar and digital merchants through sales team. As of December 31, 2021, the company served approximately 1,766,100 clients primarily small-and-medium-sized businesses; and marketplaces, e-commerce platforms, and integrated software vendors. StoneCo Ltd. was founded in 2000 and is headquartered in George Town, the Cayman Islands.

NASDAQ ended the session with StoneCo jumping 6.4% to $9.06 on Monday while NASDAQ fell 0.11% to $11,675.74.

Earnings Per Share

As for profitability, StoneCo has a trailing twelve months EPS of $0.54.

PE Ratio

StoneCo has a trailing twelve months price to earnings ratio of 16.93. Meaning, the purchaser of the share is investing $16.93 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.31%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, StoneCo’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 66.4%, now sitting on 9.91B for the twelve trailing months.

Moving Average

StoneCo’s worth is under its 50-day moving average of $9.79 and under its 200-day moving average of $9.84.

More news about StoneCo.

Losers Today

1. ObsEva SA (OBSV) – -14.3%

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

NASDAQ ended the session with ObsEva SA falling 14.3% to $0.20 on Monday while NASDAQ slid 0.11% to $11,675.74.

Earnings Per Share

As for profitability, ObsEva SA has a trailing twelve months EPS of $-2.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -373.98%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 85.2%, now sitting on 3.71M for the twelve trailing months.

More news about ObsEva SA.

2. OncoSec Medical Incorporated (ONCS) – -13.44%

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.

NASDAQ ended the session with OncoSec Medical Incorporated dropping 13.44% to $1.90 on Monday while NASDAQ slid 0.11% to $11,675.74.

Earnings Per Share

As for profitability, OncoSec Medical Incorporated has a trailing twelve months EPS of $-35.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -233.38%.

More news about OncoSec Medical Incorporated.

3. MMTec (MTC) – -13.4%

Mmtec, Inc. develops and deploys platforms that enable financial institutions to engage in securities market transactions and settlements in the People's Republic of China. It offers Internet-based securities solutions comprising Securities Dealers Trading System, which includes securities registration and clearing, account management, risk management, trading and execution, and third party access middleware; Private Fund Investment Management System that supports multi-account management, fund valuation, risk management, quantitative trading access, liquidation, and requisition management; and Mobile Transaction Individual Client System and PC Client System for Apple IOS, Android, PC, and Web. The company enables its customers to white label its trading interface, as well as select modular functionalities. It serves hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with MMTec falling 13.4% to $1.81 on Monday, following the last session’s downward trend. NASDAQ slid 0.11% to $11,675.74, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, MMTec has a trailing twelve months EPS of $-0.156.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.61%.

More news about MMTec.

4. Meten EdtechX Education Group Ltd. (METXW) – -10.54%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. falling 10.54% to $0.04 on Monday while NASDAQ slid 0.11% to $11,675.74.

Yearly Top and Bottom Value

Meten EdtechX Education Group Ltd.’s stock is valued at $0.04 at 16:32 EST, way below its 52-week high of $0.07 and higher than its 52-week low of $0.04.

More news about Meten EdtechX Education Group Ltd..

5. LM Funding America (LMFA) – -10.31%

LM Funding America, Inc., through its subsidiary, LM Funding, LLC, operates as a specialty finance company. It provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado, and Illinois. The company offers funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It is also involved in the business of purchasing delinquent accounts on various terms tailored to suit each Association's financial needs, including under its New Neighbor Guaranty program. In addition, the company provides medical insurance products for international travelers. LM Funding America, Inc. was founded in 2008 and is based in Tampa, Florida.

NASDAQ ended the session with LM Funding America falling 10.31% to $0.86 on Monday, after three consecutive sessions in a row of losses. NASDAQ slid 0.11% to $11,675.74, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, LM Funding America has a trailing twelve months EPS of $-1.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.59%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 18.5%, now sitting on 835.95k for the twelve trailing months.

More news about LM Funding America.

6. Inovio Pharmaceuticals (INO) – -9.09%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals dropping 9.09% to $1.20 on Monday while NASDAQ slid 0.11% to $11,675.74.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Inovio Pharmaceuticals’s stock is considered to be oversold (<=20).

Moving Average

Inovio Pharmaceuticals’s value is way under its 50-day moving average of $1.59 and way below its 200-day moving average of $1.89.

Sales Growth

Inovio Pharmaceuticals’s sales growth is negative 59.5% for the present quarter and 0.5% for the next.

More news about Inovio Pharmaceuticals.

7. Canaan (CAN) – -8.94%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components primarily in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has a strategic cooperation with Northern Data AG in the areas of artificial intelligence development, blockchain technology, and datacenter operations. Canaan Inc. was founded in 2013 and is based in Beijing, the People's Republic of China.

NASDAQ ended the session with Canaan sliding 8.94% to $2.50 on Monday, following the last session’s upward trend. NASDAQ slid 0.11% to $11,675.74, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.212.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.53%.

More news about Canaan.

8. Clean Energy Fuels (CLNE) – -8.62%

Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions, primarily in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2021, the company served approximately 1,000 fleet customers operating approximately 48,000 vehicles; and owned, operated, or supplied approximately 548 fueling stations in 42 states in the United States and 25 fueling stations in Canada. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.

NASDAQ ended the session with Clean Energy Fuels falling 8.62% to $4.56 on Monday, following the last session’s upward trend. NASDAQ dropped 0.11% to $11,675.74, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Clean Energy Fuels has a trailing twelve months EPS of $-0.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.69%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 46%, now sitting on 398.34M for the twelve trailing months.

More news about Clean Energy Fuels.

9. Tattooed Chef (TTCF) – -8.33%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, and plant-based burgers. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores. As of December 31, 2021, it operated approximately 14,000 retail outlets. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef dropping 8.33% to $1.16 on Monday while NASDAQ dropped 0.11% to $11,675.74.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-0.069.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.72%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 113.3% and a negative 9.5%, respectively.

Volatility

Tattooed Chef’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.17%, a negative 0.95%, and a positive 5.16%.

Tattooed Chef’s highest amplitude of average volatility was 4.47% (last week), 4.98% (last month), and 5.16% (last quarter).

Yearly Top and Bottom Value

Tattooed Chef’s stock is valued at $1.16 at 16:32 EST, way under its 52-week high of $13.23 and way above its 52-week low of $1.05.

Sales Growth

Tattooed Chef’s sales growth is 2.3% for the current quarter and negative 9.6% for the next.

More news about Tattooed Chef.

10. DexCom (DXCM) – -7.68%

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

NASDAQ ended the session with DexCom falling 7.68% to $113.47 on Monday, after two successive sessions in a row of gains. NASDAQ dropped 0.11% to $11,675.74, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, DexCom has a trailing twelve months EPS of $5.2.

PE Ratio

DexCom has a trailing twelve months price to earnings ratio of 21.8. Meaning, the purchaser of the share is investing $21.8 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.19%.

Volatility

DexCom’s last week, last month’s, and last quarter’s current intraday variation average was 2.75%, 0.74%, and 1.85%.

DexCom’s highest amplitude of average volatility was 2.87% (last week), 2.17% (last month), and 1.85% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DexCom’s stock is considered to be oversold (<=20).

More news about DexCom.

Stay up to date with our winners and losers daily report